Encouraging response rates and high mobilization success with brentuximab vedotin plus GDP in adult relapsed/refractory classical Hodgkin lymphoma: A real-world study

NAMDAROĞLU S., BATGİ H., Kakcı M., Öztürk O. C., Şeker Ö., GÜZEL B., ...Daha Fazla

Leukemia Research Reports, cilt.25, 2026 (ESCI, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1016/j.lrr.2026.100584
  • Dergi Adı: Leukemia Research Reports
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
  • Anahtar Kelimeler: Autologous stem cell transplantation, Brentuximab vedotin, GDP, Hodgkin lymphoma, Real-world study, Salvage therapy
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background: Relapsed or refractory classical Hodgkin lymphoma (R/R cHL) remains challenging, and achieving metabolic complete response prior to autologous stem cell transplantation (ASCT) is important. GDP is a generally well-tolerated outpatient regimen, while brentuximab vedotin (BV) has demonstrated encouraging activity in salvage combinations. Adult real-world data on BV+GDP remain limited. Methods: Eight adult R/R cHL patients received BV+GDP between May 2023 and March 2025. Responses (Lugano 2014), toxicities (CTCAE v5.0), and mobilization outcomes were retrospectively evaluated. Results: Complete response was achieved in 7/8 patients (87.5%). All responders underwent successful stem-cell mobilization and ASCT. Toxicities were manageable, with no febrile neutropenia or renal toxicity observed. At a median follow-up of 10.6 months, all patients remained alive and progression-free. Conclusion: BV+GDP showed encouraging activity with acceptable tolerability, supporting further prospective evaluation.